Hem Securities is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 5711 in its research report dated November 30, 2021.

Divi’s Labs: Green chemistry gives it the upper hand

Divi's Labs has a strong focus on ‘green chemistry’, helping it to reduce wastage through technology adoption, leading to better profitability and relationship with global clients

Buy Divi’s Laboratories; target of Rs 5750: Motilal Oswal

Motilal Oswal is bullish on Divi’s Laboratories recommended buy rating on the stock with a target price of Rs 5750 in its research report dated August 08, 2021.

Buy Divis Laboratories: target of Rs 4810: Sharekhan

Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 4810 in its research report dated May 28, 2021.

Buy Divi’s Laboratories; target of Rs 4850: Motilal Oswal

Motilal Oswal is bullish on Divi’s Laboratories recommended buy rating on the stock with a target price of Rs 4850 in its research report dated May 30, 2021.

Buy Divi’s Lab; target of Rs 4530: Motilal Oswal

Motilal Oswal is bullish on Divi’s Lab recommended buy rating on the stock with a target price of Rs 4530 in its research report dated March 24, 2021.

Buy Divis Laboratories: target of Rs 4500: Sharekhan

Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 4500 in its research report dated March 23, 2021.

Gladiator Stocks - Divis Laboratories: ICICI Direct

According to ICICI Direct, Buy Divis Laboratories in the range of Rs 3280.00–3325.00 for target price of Rs 3740.00 with a stop loss of Rs 3110.00. Time Frame: Six months.

Buy Divi’s Laboratories; target of Rs 4440: ICICI Direct

ICICI Direct is bullish on Divi’s Laboratories has recommended buy rating on the stock with a target price of Rs 4440 in its research report dated February 06, 2021.

Divi’s Labs: All set to reap investments

Since the macro context is fragile, eventually liquidity will continue to chase cash rich and cash flow positive businesses such as Divi’s Labs

PI Industries: Custom synthesis giant waiting for another orbit

We like the PI Industries' focus on custom synthesis and manufacturing which has helped it become a “partner of choice” for global agrochemical majors

Gland Pharma Q3: Strong and clean play on global generic injectables; accumulate

We believe dominance of profit/royalty-sharing aspect in the business model distinguishes Gland Pharma from other contract manufacturers

Buy Divi's Laboratories; target of Rs 4425: ICICI Direct

ICICI Securities is bullish on Divi's Laboratories recommended buy rating on the stock with a target price of Rs 4425 in its research report dated December 30, 2020.

Buy Divis Laboratories: target of Rs 4175: Sharekhan

Sharekhan is bullish on Divis Laboratories recommended buy rating on the stock with a target price of Rs 4175 in its research report dated December 04, 2020.

Buy Divis Laboratories: target of Rs 3800: Sharekhan

Sharekhan is bullish on Divis Laboratories recommended buy rating on the stock with a target price of Rs 3800 in its research report dated November 06, 2020.

Buy Divi’s Laboratories; target of Rs 3900: Motilal Oswal

Motilal Oswal is bullish on Divi’s Laboratories recommended buy rating on the stock with a target price of Rs 3900 in its research report dated November 08, 2020.

Divi’s Labs: Improved growth visibility for custom synthesis, but valuation rich

Divi's Labs result re-emphasise the fact that the global trend of de-risking supply chains away from China is adding to order enquires and product dispatches

Accumulate Divi's Laboratories; target of Rs 3515: Dolat Capital Market

Dolat Capital Market recommended accumulate rating on Divi's Laboratories with a target price of Rs 3515 in its research report dated November 08, 2020.

Buy Divi's Laboratories; target of Rs 4205: ICICI Direct

ICICI Direct is bullish on Divi's Laboratories recommended buy rating on the stock with a target price of Rs 4205 in its research report dated November 08, 2020.

Buy Divi’s Laboratories; target of Rs 3350: Motilal Oswal

Motilal Oswal is bullish on Divi’s Laboratories recommended buy rating on the stock with a target price of Rs 3350 in its research report dated August 09, 2020.

Buy Divis Laboratories; target of Rs 3400: Sharekhan

Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 3400 in its research report dated August 07, 2020.

Buy Divi's Laboratories; target of Rs 3260: ICICI Direct

ICICI Direct is bullish on Divi's Laboratories has recommended buy rating on the stock with a target price of Rs 3260 in its research report dated August 09, 2020.

Divi’s labs: Expensive for a reason

Divi’s ongoing capex plan should be helpful in capitalising on the opportunity stemmiing from drug shortages, the pandemic and the shift away from China

Buy Divis Laboratories target of Rs 2700: Sharekhan

Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 2700 in its research report dated June 08, 2020.

Hold Divi's Laboratories; target of Rs 2355: ICICI Direct

ICICI Direct recommended hold rating on Divi's Laboratories with a target price of Rs 2355 in its research report dated June 09, 2020.